Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma
Status:
Withdrawn
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of
JNJ-39758979 compared with placebo in patients with uncontrolled asthma despite current
treatment with inhaled corticosteroids and/or long-acting beta 2-agonist (LABA) and/or
montelukast for at least 4 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.